Selvita Announces Q1 2026 Results and Strategic Options Review for Future Growth

Selvita Reports Q1 2026 Financial Results and Strategic Options Review

On May 21, 2026, Selvita S.A. (WSE: SLV), a prominent player in Europe's Drug Discovery and Development sector, shared its financial performance for the first quarter of 2026. Alongside this, the company announced the initiation of a strategic options review to explore growth avenues and maximize long-term shareholder returns.

Financial Highlights

During Q1 2026, Selvita's operating revenues reached EUR 19.1 million, meeting the upper end of the initial estimate range of EUR 18.4-19.3 million. The EBITDA margin stood at 14%, slightly above the anticipated range of 13-16%. The culmination of a cost-saving initiative began in the second half of 2025 allowed the firm to decrease operating costs by approximately EUR 1.5 million in this quarter.

The Drug Development segment performed well, with commercial revenues rising by 6% year-over-year to EUR 6.2 million, contributing to 35% of total commercial revenues for the group. This segment's EBITDA registered at EUR 1.7 million, a modest increase of 2% YOY. Meanwhile, the Drug Discovery segment's commercial revenue totaled EUR 11.6 million, down from EUR 15.6 million the previous year, with an EBITDA of EUR 1.0 million compared to EUR 1.9 million recorded in Q1 2025. This decline is attributed to a challenging outsourced drug discovery service market and project delays.

Strategic Options Review

Selvita’s management has taken a proactive stance regarding market challenges within its Drug Discovery segment, acknowledging pressures in the European outsourced services sector. Nonetheless, they perceive encouraging trends stemming from improved biotechnology funding and emerging pipeline opportunities that could enhance performance throughout the remainder of 2026.

Boguslaw Sieczkowski, Co-Founder and CEO, highlighted the importance of maintaining an upward trajectory amid market volatility, particularly in the biotechnology landscape, emphasizing growth strategies tailored for both Drug Development and Drug Discovery markets. The Drug Development unit, having seen consistent growth of 20-25% over recent years, is now recognized as a critical component of Selvita's revenue streams.

To facilitate its strategic analysis, Selvita has enlisted Rothschild & Co as its financial adviser, with a comprehensive evaluation of various pathways, including potential take-private transactions or the acceleration of mergers and acquisitions initiatives. This stage is not time-bound, allowing for an exhaustive analysis of available options.

Backlog and Future Outlook

As of May 18, 2026, Selvita's total backlog stood at EUR 58.1 million, slightly lower than the prior year's EUR 58.9 million. The discrepancies between the Drug Discovery and Drug Development segments were evident, with the former's backlog declining by 13% to EUR 35.3 million. In contrast, the Drug Development backlog increased by 15% to EUR 19.4 million, signaling robust demand for their services in that area.

Moreover, Selvita is set to launch an aggressive technology development program supported by significant non-dilutive grants amounting to EUR 26.4 million. Nearly half of this, EUR 12.0 million, is earmarked for advancing its service offerings for the coming years.

In the long term, while challenges persist within certain markets, Selvita's outlook remains optimistic. The group aims to enhance its offerings, improving profitability through operational efficiency and an invested focus on high-value services and automation within its Drug Discovery segment.

Conclusion

With its Q1 results and ongoing strategic review, Selvita is positioning itself to navigate the complexities of the biotechnology landscape effectively. The company remains committed to delivering exceptional service and operational stability while exploring avenues that can drive performance and shareholder value. A detailed discussion of Selvita's Q1 outcomes and strategic direction is scheduled for a webcast on May 21 at 11:00 CET, available at live.selvita.com.